NLR, ELR and SII Index as Biomarkers of Asthma Control

ConditionAsthma Control

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorShaimaa Ali Mohammed

About this trial

This is Case control study aims to study Neutrophil-to-Lymphocyte Ratio (NLR), Eosinophil-to-Lymphocyte Ratio (ELR), and Systemic Immune Inflammation (SII) Index as Biomarkers of Asthma Controlin adult patients with bronchial asthma.

This study will investigate the association between these inflammatory indices and the level of asthma control to assess their potential value as simple ,readily available and cost -effective biomarkers in clinical practice.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adult patients aged > 18 years.

Confirmed diagnosis of bronchial asthma according to Global Initiative for Asthma (GINA) guidelines.

Patients who provided informed consent to participate in the study.

Disqualifiers

Patients with chronic respiratory diseases other than asthma.

Acute respiratory infection within the previous 4 weeks.

Patients with hematological disorders, malignancies, autoimmune diseases, or systemic inflammatory conditions that might affect blood cell counts.

Patients taking systemic steroids, experiencing acute asthma attack (because infection may affect neutrophil level).

Trial population

The study population consists of 140 adults: 70 patients with physician-diagnosed asthma and 70 age- and sex-matched healthy controls recruited from the Chest Department of Assiut University Hospital during the study period

Trial design

Design model

Case-control

Time perspective

Prospective

Treatments tested in this trial

Complete blood count
Other intervention
Venous blood samples will be collected for CBC including neutrophil, lymphocyte, eosinophil, and platelet counts. NLR, ELR, and SII will be calculated

Treatment groups

140 Participants

are divided into 2 treatment groups

Group A: Asthma patients1 intervention

Group B: Healthy control1 intervention

Trial outcomes

Primary outcomes

Asthma Control Test (ACT) score.

Asthma control will be assessed using the Asthma Control Test (ACT; score range 5-25 points) at baseline. The ACT score will be analyzed for its correlation with neutrophil-to-lymphocyte ratio (NLR), eosinophil-to-lymphocyte ratio (ELR), and systemic immune-inflammation index (SII).

Time frame

Baseline (day 1)

Secondary outcomes

Comparison of the accuracy of NLR, ELR, and SII to determine the most reliable biomarker for asthma control assessment.

To compare the diagnostic performance of NLR, ELR, and SII in distinguishing controlled from uncontrolled asthma and to identify the biomarker with the highest predictive accuracy.

Time frame

Baseline(day 1)

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Shaimaa Ali Mohammed

Lead sponsor

Assiut University

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: